

Patient Enrollment Form for VOXZOGO® (vosoritide) for injection

Fax completed form with prescriber's signature to **1.833.869.0323** To learn more about BioMarin RareConnections™ call **1.833.VOXZOGO** (1.833.869.9646), **hours M−F, 8** AM**−8** PM (ET)



### All required fields are purple and bolded

	First Name		Middle Initial	Last Name		Suffix		
	ate of Birth (mm/dd/yyyy) Gender 🗆 Male 🗆 Female 🗆 Other							
PATIENT	Address						Floor/Suite/Unit	
	City					State	ZIP Code	
	Primary Phone Mobile Phone (same as primary) Email							
	Preferred Method of Contact Primary Phone Mobile Phone		Preferred Language: English Spanish					
	Authorized Representative Name (if ap	Relationship to Patient			ship to Patient			
	Phone	Email						
	First Name			Last Name				
	Specialty		NPI Number					
	State License Number Medi		Medicaid Number	Tax ID				
ж.	Name of Institution/Practice							
PRESCRIBER	Address					Floor/Suite/Unit		
PRES	City			State ZIP Code			ZIP Code	
	Phone	Fax		Email				
	Preferred Method of Contact       Phone       Fax       Email         Primary Contact Name (if different from prescriber)       Email       Email							
	Phone Fax Email							
	Provide copies of all medical and prescription cards — front and back							
	Patient has no insurance Primary Medical Insurance Name					Insurance Phone		
В	Subscriber Name			Relationship to Patient				
INSURANCE	Member ID	Group	Plan Code					
INSU	Prescription (PBM) Insurance Name				Insurance Phone			
	Subscriber Name							
	Member ID	RxBIN		RxPCN		R×GROUP		

Patient's Full Name	Pati	ent's	Full	Name
---------------------	------	-------	------	------

CLINICAL / DIAGNOSIS	ICD-10-CM Q77.4 is	s used for both achon ndroplasia 5 years of ) (please list)	droplasia and hypochondroplasia; VOXZ	nosis (please specify) OGO® (vosoritide) is only indicated for inc open. If patient has hypochondroplasia, s Current weight (kg)				
	Inject subcutaneous daily dose based on the patient's weight and the VOXZOGO concentration table below. If patient's body weight is < 10 kg, contact the Specialty Pharmacy for proper dosing.							
	Body Weight (kg)		VOXZOGO 0.4 mg/vial NDC: 68135-0082-36 10 doses Diluent (Sterile Water for Injection, USP): 0.5 mL Concentration: 0.8 mg/mL	VOXZOGO 0.56 mg/vial NDC: 68135-0119-66 10 doses Diluent (Sterile Water for Injection, USP): 0.7 mL Concentration: 0.8 mg/mL	VOXZOGO 1.2 mg/vial NDC: 68135-0181-93 10 doses Diluent (Sterile Water for Injection, USP): 0.6 mL Concentration: 2 mg/mL			
			Da	ily injection volume (r	nl.)			
	10-11							
			0.3 mL (0.24 mg)	0.35 mL (0.28 mg)				
	12-16 17-21		0.3 mL (0.22 mg)					
	22-32			0.5 mL (0.4 mg)				
	33-43				0.25 mL (0.5 mg)			
	44-59				0.3 mL (0.6 mg)			
	60-89				0.35 mL (0.7 mg)			
	≥90				0.4 mL (0.8 mg)			
lon	Quantity to Dispense	Refills	Sele <mark>ct product to order b</mark> elow					
CRIP	□ 1-month supply (3 kits)		UVXZOGO 0.4 mg/vial	UVXZOGO 0.56 mg/vial	U VOXZOGO 1.2 mg/vial			
PRESCRIPTION	□ 3-month supply (9 kits) Other	#	<b>Directions for use</b> Reconstitute vial with 0.5 mL of sterile water and inject mL subcutaneously once daily	<b>Directions for use</b> Reconstitute vial with 0.7 mL of sterile water and inject mL subcutaneously once daily	Directions for use Reconstitute vial with 0.6 mL of sterile water and inject mL subcutaneously once daily			
			10 single-dose prefilled diluent syringes ot interchangeable.	s (Sterile Water for Injection, USP), 10 ne	edles, and 10 syringes.			
	Ancillary Supplies—Specialty Pharmacy will provide the following items to patients on first dispense and as needed thereafter: Sharps Container, Alcohol wipes and Band-Aids.							
	Special Delivery Instructions							
	Prescriber Declaration: I understand and agree that, as the prescriber, I will comply with my state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to me, as the prescriber. I verify that the patient and prescriber information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed, VOXZOGO based on my professional judgment of medical necessity. I authorize BioMarin Pharmaceutical Inc., its affiliates, agents and contractors (collectively, "BioMarin") to act on my behalf for the limited purpose of transmitting this prescription by any means under applicable law to the appropriate pharmacy designated by the above-named patient utilizing their benefit plan. I also authorize the BioMarin RareConnections™ program to perform any steps necessary to secure reimbursement for VOXZOGO, including but not limited to insurance verification and case assessment. I understand that BioMarin or BioMarin RareConnections may need additional information, and I agree to provide it as needed for the purposes of securing reimbursement.							
	Prescriber's Signature. Please make a selection							
		·						
		ture/Dispense as Wr		Prescriber's Signature/Substitution Pe (no stamps or initials)	rmitted Date			



References to "you," "your," "I," "me," "my," etc. in this form are to the patient, even if an authorized representative is signing this form on the patient's behalf.

# FOR BIOMARIN TO ASSIST YOU WITH ITS MEDICINES AND RELATED CARE, YOU WILL NEED TO PROVIDE CONSENT TO BOTH YOUR HEALTHCARE PROVIDER AND BIOMARIN:

- · Your healthcare provider needs your written consent to release your protected health information (PHI) to BioMarin
- BioMarin needs your written consent to share your information with service providers such as laboratories and pharmacies to assist you with
   accessing services that support your treatment
- BioMarin needs your consent to contact you with marketing and other communications about BioMarin's products, services, programs, and
  other topics of interest for marketing, educational, or other purposes; to assist you in getting help through additional services that support your
  treatment plan; and to allow you to provide feedback to BioMarin through market research
- As described below, your consent is voluntary and is not required for treatment, medications, or other care. Your consent is required for BioMarin to provide the product support services described here

## SECTION A: CONSENT TO SHARE HEALTH INFORMATION FOR PATIENT SUPPORT SERVICES

By signing this Patient Consent Form (PCF), I hereby authorize my healthcare providers, health insurance carriers, laboratory providers, and pharmacy providers (collectively, Healthcare Entities) to use and disclose my individual health and identifying information, including but not limited to health insurance information, medical diagnosis and condition (including but not limited to laboratory test results such as diagnostic results as well as test results related to diagnosis or supportive testing), prescription information, and name, date of birth, sex, address, and telephone number to BioMarin and its agents and representatives, including but not limited to third parties authorized by BioMarin. I further authorize BioMarin to use my individual health and identifying information to administer the patient support program through BioMarin RareConnections<sup>™</sup> and BioMarin's Clinical Coordinator Program and for the following additional purposes:

- to contact my healthcare provider and collect, enter, and maintain my health information in a database;
- to contact my insurers as needed to verify my insurance coverage, review reimbursement requirements, verify other financial assistance for which I might be eligible, assist with the processing of claims, or otherwise assist in obtaining coverage or financial assistance for my treatment, including but not limited to in relation to post-administration monitoring;
- to determine eligibility for program offerings, including but not limited to financial assistance services; and
- to contact me to follow up on any BioMarin RareConnections enrollment requirements, receive education, discuss and provide information
  and education on my treatment and any follow-up requirements, discuss the effectiveness of support services, and provide support services,
  education, and adherence reminders such as to take my BioMarin medication. BioMarin Clinical Coordinators do not work under the direction
  of your healthcare provider or give medical advice. BioMarin Clinical Coordinators are trained to direct patients to their healthcare provider for
  treatment-related advice

Once my health information has been disclosed to BioMarin, I understand that federal privacy laws no longer protect the information. However, BioMarin agrees to protect my health information by using and disclosing it only for purposes authorized in this PCF or as required by law or regulations. California residents, to learn more about the information BioMarin may collect about you, how we use that information, and your rights under the California Consumer Privacy Act (CCPA), please review our CCPA Privacy Policy, available at biomarin.com/data-privacy-center. I understand that pharmacy providers, or others working on their behalf, may receive remuneration from BioMarin in exchange for the health information and/or for any therapy support services provided.

# This PCF expires in ten (10) years, or such shorter amount of time required by applicable state law, after the date I sign it as indicated by the date next to my signature, unless otherwise canceled earlier as set forth below. I understand I have a right to receive a copy of this PCF.

I understand that I may refuse to sign this PCF. I further understand that my treatment (including with a BioMarin product), payment for treatment, insurance enrollment, or eligibility for insurance benefits are not conditioned upon my agreement to sign this PCF, but if I do not sign it, or if I later cancel it, I will not be able to receive BioMarin's therapy support services.

I understand that I may cancel this PCF at any time by mailing a letter to BioMarin at BioMarin RareConnections at 680 Century Point, Lake Mary, FL 32746 or emailing support@biomarin-rareconnections.com. Canceling this PCF will end my consent for my Healthcare Entities to further disclose my health information to BioMarin after they are notified of my cancellation but will not affect previous disclosures by them pursuant to this PCF. Canceling this PCF will end my consent for my eligibility for health insurance.

## SECTION B: CONSENT FOR MARKETING/OTHER COMMUNICATIONS

By signing this Patient Consent Form (PCF), I hereby authorize my Healthcare Entities to use and disclose my individual health and identifying information to BioMarin for marketing purposes or to otherwise provide me with information about BioMarin products, services, research, clinical trials, and programs or other topics of interest, and to conduct market research or otherwise ask me about my experience with or thoughts about such topics. I understand and agree that BioMarin and companies working with BioMarin may use my individual health and identifying information to contact me by mail, email, fax, telephone call, or text message for these purposes. I understand and agree that any information that I provide may be used by BioMarin to help develop new products, services, and programs. I further understand that BioMarin will not sell or transfer my personal data to any unrelated third party for marketing purposes without my express permission.

## SECTION C: BIOMARIN CO-PAY ASSISTANCE PROGRAM ELIGIBILITY

The BioMarin Co-Pay Assistance Program pays for eligible out-of-pocket costs, where applicable, associated with a qualifying BioMarin therapy up to a maximum amount per calendar year. The program is valid ONLY for gualifying patients residing in the 50 U.S. states or in Puerto Rico, where not prohibited by law, with commercial insurance who have a valid prescription for an FDA-approved indication for the qualifying BioMarin therapy. By participating in the program, patients acknowledge that they understand and agree to comply with the complete program terms and conditions available at BioMarin-RareConnections.com or on request by contacting BioMarin RareConnections at 1.866.906.6100.

#### 1 To authorize your consent, please complete all fields below.

Patient's First Name	Middle Initial Patient's Last Name	Suffix	Date of Birth	Gender 🛛 Mal	e 🗆 Fema	le 🛛 Other
Patient's/Authorized Represe	entative's Name (if applicable)	Relation	ship to Patient			
Patient's/Authorized Represe	entative's Address	Floor/Suite/Unit	City		State	ZIP Code
Preferred Method of Contact	(please specify)					
☐ Mobile Phone (leave blan	k if mobile is primary phone)		_ 🗆 Email			
Preferred Language	nolish 🔲 Spanish 🔲 Other Language (pl	lease specify)				

#### Please read and sign below. 2

I have read and understand Section A in this PCF, the Consent to Share Health Information for Patient Support Services, and agree to the terms stated therein. A consent signature is required in order to receive BioMarin services.

Patient's/Authorized Representative's Signature	Date
Print Authorized Representative's Name (if applicable)	Relationship to Patient

#### Please read and sign below. 3

I have read and understand Sections B and C in this PCF, the Consent for Marketing/Other Communications and the Co-Pay Assistance Program Eligibility, and agree to the terms stated therein.

Patient's/Authorized Representative's Signature

Print Authorized Representative's Name (if applicable)

## Print and fax your completed form (both pages) to 1.888.863.3361.

Note for healthcare providers: once your patient has completed this form, provide a copy to them and place the original in the patient's medical record.



## BOMARIN

Relationship to Patient

Date

Relationship to Patient